Zhou J, Wang X, Feng L, et al. - Via this 8-week, multicenter, randomized, single-blind, active-controlled trial, venlafaxine was compared with fluoxetine in the treatment of postmenopausal major depressive disorder (MDD), focusing on the efficacy and safety. Randomization involved 184 women. In full analysis set, there were 172 patients (venlafaxine, n = 82; fluoxetine, n = 90). Findings not only showed the good tolerability of venlafaxine but also revealed that it conferred a greater improvement in the treatment of postmenopausal MDD when compared with fluoxetine.